AstraZeneca PLC has priced its newly approved lung cancer therapy at a "competitive" rate, at $12,750 (£8,944) per patient per month, keeping its eyes on a future first-line use indication.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?